



Contact: Tricia J. Richardson
Novavax, Inc.
240-268-2031

Novavax Announces Poster Presentation at the 47th Annual Meeting of the IDSA

ROCKVILLE, MD (October 29, 2009) – /PRNewswire-FirstCall/ - Novavax, Inc. (NASDAQ: NVAX) a clinical-stage vaccine company, announced today that its abstract has been selected for poster presentation at the Infectious Diseases Society of America (IDSA) 47th Annual meeting being held in Philadelphia, Pennsylvania from October 29 – November 1, 2009.

Poster presentation: “Safety and Immunogenicity of a Recombinant Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Healthy Adults”, Penny Heaton, M.D., Maria Allende, M.D., Kathy Lenhard, R.N., Mike Massare, PhD., and Mark Wolff, PhD. Saturday October 31, 2009 12:30 pm to 2:00 pm., Pennsylvania Convention Center, Poster Hall A.

About the 47th Annual Meeting of the IDSA

This conference will showcase abstract presentations containing outstanding, noteworthy science; and expanded roster of challenging interactive sessions; symposia on management of difficult pathogens, such as MRSA, *Clostridium difficile*, and drug-resistant mycobacteria, gram-negative bacillia and fungi; and the promises and challenges of new vaccines. The Special Plenary Session and Named Lectures will highlight important advancements as well as challenges in the world of infectious diseases. Additional information is available at www.idsociety.org.

About Novavax

Novavax, Inc. is a clinical-stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP -based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The Company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company’s website: www.novavax.com

###